Mielucin review

Mielucin is a cancer medication known to slow down the neoplastic activity of malignant cells. It is a non-specific cell type alkylating antineoplastic agent that was initially created as a therapeutic medication for chronic myeloid leukemia and has been reclassified as a generic medication for cancer cells.

This medication controls the tumor formation and significantly slows down metastasis of cancer cells to other regions of the body. It is not able to entirely stop the progress of the cancer cells, as it is incapable of reversing the overall cellular aberration effects of the cancer cells. Cytogenic abnormalities may still progress, but at a much slower rate than without the medication.

Mielucin is most often given to cancer patients susceptible to chemotherapy and medication induction therapy. The medication works on a cellular level, producing Guanine-guanine strands of genetic output as it attacks the carbon strand in the mesylate group in a malignant cancer cell. This has large success rates and results in an apoptotic state. The result can decrease overall strength as massive cellular destruction on the target area is occurring, which is evidenced by destruction of normal cells, especially in bone marrows.

Mielucin is a good alternative for non-operative stem cell transplantation, therefore increasing the patient’s receptivity for an oncoming transplant of stem cells.

Cancer patients should be provided with all of the proper information regarding the medication and the proper supervision and expertise of a qualified healthcare professional.

Mielucin is a palliative medication prescribed in dosages of 60 micrograms per body weight in kilos, with a maximum of 4 milligrams per day. For treatment of Polycythemia vera, 4 to 6 milligrams is recommended per day over 4 to 6 weeks. For thrombocythaemia, 2 to 4 milligrams per day is suggested. Conditioning therapeutic plans suggest about 3.5 to 4 milligram per body weight in kilos per day, given in four doses, totaling 14 to 16 milligrams per kilo body weight.

Side effects include general toxicity leading to fibrosis in the pulmonary tract, seizures, wasting of the muscles and organs, and cases of liver malfunction and failure. For seizures, phenytoin cN be used to lessen the occurrence.

Talk with your healthcare professional about any medications that you are already using to determine possible drug interactions. Special consideration must be given to antifungal medications such as azole variants. This medication is contraindicated with phenothiazines and other cancer medications such as cyclosporine. If contraindications of medication is suspected, take the medication cautiously three days after last previous medication is used. Acetaminophen is not to be used in conjunction with Mielucin because it raises blood levels and may increase the risk of complicated hypertension.

Mielucin has the following structural formula:

Chemical structure of mielucin

• Molecular formula of mielucin is C6H14O6S2
• Chemical IUPAC Name is 1,4-bis(methylsulfonyloxy)butane
• Molecular weight is 246.304 g/mol

Generic name: Busulfan

Brand name(s): Busulfex, Busulphan, Busulphane, Buzulfan, Citosulfan, Leucosulfan, Mablin, Mielevcin, Mielosan, Milecitan, Mileran, Misulban, Mitosan, Mitostan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Sulphabutin

  Your Mielucin review